1. 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (September 2015) Authors: Rini, B.; Stenzl, A.; Zdrojowy, R.; Kogan, M.; Shkolnik, M.; Oudard, S.; Weikert, S.; Bracarda, S.; Crabb, S.; Bedke, J.; Ludwig, J.; Maurer, D.; Mendrzyk, R.; Mahr, A.; Fritsche, J.; Weinschenk, T.; Singh, H.; Kirner, A.; Reinhardt, C.; Eisen, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗